HOUDINI LINK

Project HOUDINI LINK (Hospital Opioid Use Disorder treatment INItiation and LINKage to care) is a SAMHSA funded project that studies the efficacy of a novel 6-month care coodination program, consisting of lay patient navigators, contingency management and motivational interviewing, on (1) linkage rates to community-based treatment (2) ongoing treatment engagement and (3) health care utilization for patients initiating medications for OUD while hopsitalized at Zuckerberg San Francisco General Hopsital.

Z-1701

Z-1701 is an outpatient randomized within subject placebo-controlled human laboratory investigation of analgesia (as assessed with quantitative sensory testing; QST) from ketamine alone and in combination with hydromorphone in buprenorphine-maintained participants. The goals of this project are to characterize the analgesic, subjective, and physiologic effects of ketamine combined with hydromorphone in patients on buprenorphine maintenance for opioid use disorder.

CTN-0080

CTN-0080 (Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs)) is a multi-site randomized controlled non-inferiority clinical trial that evaluates the impact of treating OUD in pregnant women with extended-release buprenorphine (BUP-XR), compared to sublingual buprenorphine (BUP-SL), on mother and infant outcomes.

Z-1901

Z-1901 is a controlled human laboratory study examining how two stressors, chronic pain and mild opioid withdrawal, affect decision making in patients on methadone maintenance. This study will test how chronic pain is associated with increases in impulsive decision making in OUD, whether impulsive decision making is greater when undergoing opioid withdrawal, and how pain catastrophizing may modify the association between withdrawal and impulsive decision making in patients with chronic pain and OUD.

Z-2001

Z-2001 examines the acceptability and feasibility of an FDA-cleared prescription digital therapeutic, reSET®/reSET-O® in patients with OUD enrolled at OTOP/Ward 93 during the COVID-19 pandemic. reSET® and reSET® are smartphone applications that combine interactive cognitive behavioral therapy modules, in-app reminders to track use and triggers, as well as financial incentives for module completion and in-clinic urine drug screen results.
Lastly, we conducted qualitative and quantitative data on the myriad of regulatory and practice changes that occurred in the delivery of care to patients with OUD because of the COVID-19 pandemic. For example, we demonstrated that distributing flip phones could improve adherence with telephone counseling and may improve retention in treatment in patients enrolled in a licensed opioid treatment program (OTOP/Ward 93).

OTOP Drug Surveillance Project

The Project seeks to characterize drugs and adulterants currently present in the drug supply in San Francisco including xylazine (sometimes referred to as “Tranq”), nitazene analogs (sometimes referred to as “iso”), fentanyl analogues, and “designer” benzodiazepines by utilizing mass spectrometry to analyze urine samples collected at intake to treatment. The Project seeks to provide regularly updated information to people who use drugs and people working with them, including public health and affiliated organizations in order to help better understand and respond to the risks associated with the presence of unexpected drugs and adulterants in the drug supply.

Click to view Drug Surveillance Data